Pierre Lemieux
Geen lopende functies
Vermogen: 2 562 $ op 30-04-2024
Profiel
Pierre Lemieux is the founder of Acasti Pharma, Inc. (founded in 2002) and Technologie BiolActis, Inc. (founded in 1998).
At Acasti Pharma, he held the title of Chief Operating & Scientific Officer from 2018 to 2023.
At Technologie BiolActis, he held the title of Chairman & Chief Executive Officer from 1998 to 2009.
Dr. Lemieux also held former positions as Director at PharmaBio Development, Inc., Director & Vice President at Supratek Pharma, Inc., Director at BioQuebec, and Director at Montreal Invivo Organization.
Dr. Lemieux earned a doctorate degree from Université Laval and an undergraduate degree from Texas University of Health Center at San Antonio.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 18-08-2023 | 875 ( 0.01% ) | 2 562 $ | 30-04-2024 |
Eerdere bekende functies van Pierre Lemieux
| Bedrijven | Functie | Einde |
|---|---|---|
| ACASTI PHARMA INC. | Oprichter | 08-05-2023 |
Technologie BiolActis, Inc.
 Technologie BiolActis, Inc. Pharmaceuticals: MajorHealth Technology Technologie BiolActis, Inc. engages in the development of biologics for the wellness industries. It specializes in the development of natural peptide mixtures for treatment and prevention of diseases like lipid and cardio-vascular disorders and metabolic syndrome. The company was founded by Eric M. Simard and Pierre Lemieux in 1998 and is headquartered in Laval, Canada. | Algemeen Directeur | 01-01-2009 |
PharmaBio Development, Inc.
 PharmaBio Development, Inc. Financial ConglomeratesFinance Part of Quintiles Transnational Corp., PharmaBio Development, Inc. operates as an investment company. The private company is based in Durham, NC. Dennis B. Gillings has been the CEO of the company since 2016. | Directeur/Bestuurslid | - |
| Montreal Invivo Organization | Directeur/Bestuurslid | - |
Supratek Pharma, Inc.
 Supratek Pharma, Inc. Pharmaceuticals: MajorHealth Technology Supratek Pharma, Inc. develops drugs and related oncology therapeutic products. It offers injectable chemotherapeutic that enhances or enables an approved anticancer drug. The firm’s products include SP1014C - a novel cabazitaxel against drug resistant prostate cancer, SP1030C - novel bendamustine against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma and SP1049C - a novel injectable anthracycline platform drug against chemoresistant cancers. The company was founded by Valery Alakhov in 1994 and is headquartered in Pointe-Claire, Canada. | Directeur/Bestuurslid | - |
Opleiding van Pierre Lemieux
| Université Laval | Doctorate Degree |
| Texas University of Health Center at San Antonio | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ACASTI PHARMA INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Technologie BiolActis, Inc.
Technologie BiolActis, Inc. Pharmaceuticals: MajorHealth Technology Technologie BiolActis, Inc. engages in the development of biologics for the wellness industries. It specializes in the development of natural peptide mixtures for treatment and prevention of diseases like lipid and cardio-vascular disorders and metabolic syndrome. The company was founded by Eric M. Simard and Pierre Lemieux in 1998 and is headquartered in Laval, Canada. | Health Technology |
BioQuebec
 BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | Health Technology |
Supratek Pharma, Inc.
Supratek Pharma, Inc. Pharmaceuticals: MajorHealth Technology Supratek Pharma, Inc. develops drugs and related oncology therapeutic products. It offers injectable chemotherapeutic that enhances or enables an approved anticancer drug. The firm’s products include SP1014C - a novel cabazitaxel against drug resistant prostate cancer, SP1030C - novel bendamustine against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma and SP1049C - a novel injectable anthracycline platform drug against chemoresistant cancers. The company was founded by Valery Alakhov in 1994 and is headquartered in Pointe-Claire, Canada. | Health Technology |
| Montreal Invivo Organization | |
PharmaBio Development, Inc.
PharmaBio Development, Inc. Financial ConglomeratesFinance Part of Quintiles Transnational Corp., PharmaBio Development, Inc. operates as an investment company. The private company is based in Durham, NC. Dennis B. Gillings has been the CEO of the company since 2016. | Finance |
